Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs

Rhea-AI Filing Summary

SLOAN HARRY reported acquisition or exercise transactions in this Form 4 filing.

Ginkgo Bioworks Holdings, Inc. director Harry Sloan received a grant of 25,000 restricted stock units on June 11, 2026. Each RSU represents a right to receive one share of Class A common stock. The RSUs vest on the earlier of June 11, 2027 or the day before the next annual meeting, if he continues serving as a non-employee director.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SLOAN HARRY

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	25,000	$0.00	--

Holdings After Transaction: Restricted Stock Units — 25,000 shares (Direct, null)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date.

Key Figures

RSUs granted: 25,000 RSUs Shares underlying RSUs: 25,000 shares Exercise price: $0.00 per share +1 more

4 metrics

RSUs granted 25,000 RSUs Grant to director Harry Sloan on June 11, 2026

Shares underlying RSUs 25,000 shares Class A common stock underlying the RSU award

Exercise price $0.00 per share RSU grant has no cash exercise price

Vesting date June 11, 2027 Earlier of June 11, 2027 or day before next annual meeting

Key Terms

Restricted Stock Units, Class A Common Stock, Non-Employee Director Compensation Program, vesting

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A Common Stock financial

"to receive one share of the Issuer's Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Non-Employee Director Compensation Program financial

"In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program"

vesting financial

"the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLOAN HARRY

(Last) (First) (Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/11/2026		A		25,000		(2)	(2)	Class A Common Stock	25,000	(1)	25,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. In accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 11, 2026, the RSUs shall vest on the earlier of June 11, 2027 or the day immediately prior to the date of the next Annual Meeting occurring after the date of grant, in either case, subject to the Reporting Person continuing in service as a Non-Employee Director through such vesting date.

Remarks:

	/s/ Karen Tepichin, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Ginkgo Bioworks (DNA) report for Harry Sloan?

Harry Sloan received a grant of 25,000 restricted stock units from Ginkgo Bioworks. These RSUs are a form of equity compensation and give him the right to receive the same number of Class A common shares upon vesting, subject to service conditions.

When do Harry Sloan’s 25,000 RSUs at Ginkgo Bioworks (DNA) vest?

The 25,000 RSUs vest on the earlier of June 11, 2027 or the day immediately before the next annual shareholder meeting. Vesting requires Harry Sloan to continue serving as a non-employee director through the applicable vesting date under the company’s director compensation program.

What does each RSU granted to Harry Sloan by Ginkgo Bioworks (DNA) represent?

Each restricted stock unit represents a contingent right to receive one share of Ginkgo Bioworks’ Class A common stock. The shares are only delivered if the vesting conditions are satisfied, linking director compensation to the company’s equity over time.

How many Ginkgo Bioworks (DNA) RSUs does Harry Sloan hold after this Form 4?

After this reported transaction, Harry Sloan holds 25,000 restricted stock units directly. These RSUs were granted at no cash cost and will convert into an equivalent number of Class A common shares if the specified vesting requirements are met.

Is Harry Sloan’s RSU grant from Ginkgo Bioworks (DNA) an open-market purchase or sale?

The RSU grant is not an open-market purchase or sale. It is a compensation-related award recorded as an acquisition on the Form 4, with zero exercise price, reflecting equity granted under the non-employee director compensation program rather than a market trade.